Cytek Biosciences has just seen its modelled fair value trimmed from US$6.00 to about US$5.69, while the average published price target has been reduced from around US$5.50 to about US$4.75.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the ...

FREMONT, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- The field of medical research has a new tool to develop vaccines, personal immunotherapies, and cures for cancer and other infectious diseases using ...

CEO Wenbin Jiang reported that "second quarter revenue in 2025 was $45.6 million, down $1 million or 2.2% compared to the second quarter of 2024." He highlighted "lower product revenue in EMEA and ...

FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc.

Cytek Biosciences, Inc. announced that it will report its financial results for the fourth quarter and full year 2024 on February 27, 2025, after market close. A conference call to discuss these ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The seven-year-old Fremont company, last valued at $1 ...

Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 Total revenue on a non-GAAP constant currency basis was $50.0 million Organic revenue for Cytek’s existing ...

Cytek is supporting ISAC in a shared mission to extend flow cytometry reach worldwide. In this effort, Cytek has launched a two-part research initiative. In the first phase of the program, Cytek is ...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...